MENU
+Compare
XBI
ETF ticker: NYSE ARCA
AS OF
Feb 21 closing price
Price
$91.70
Change
-$1.02 (-1.10%)
Net Assets
5.94B

XBI stock forecast, quote, news & analysis

Category: @Health
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for XBI with price predictions
Feb 20, 2025

XBI's RSI Indicator recovers from oversold territory

The RSI Indicator for XBI moved out of oversold territory on January 15, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In of the 27 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where XBI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for XBI just turned positive on February 19, 2025. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

XBI moved above its 50-day moving average on February 19, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 242 cases where XBI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for XBI moved below the 200-day moving average on January 21, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Biotech ETF ETF is 9.44B. The market cap for tickers in the group ranges from 65.87M to 322.43B. ABBV holds the highest valuation in this group at 322.43B. The lowest valued company is MRSN at 65.87M.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Biotech ETF ETF was 39%. For the same ETF, the average monthly price growth was 107%, and the average quarterly price growth was 306%. EDIT experienced the highest price growth at 67%, while CABA experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Biotech ETF ETF was 16%. For the same stocks of the ETF, the average monthly volume growth was 3% and the average quarterly volume growth was 81%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 79
Price Growth Rating: 60
SMR Rating: 87
Profit Risk Rating: 79
Seasonality Score: -51 (-100 ... +100)
View a ticker or compare two or three
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com